Skip to main content

Advertisement

Table 3 Post-operative outcomes of HCC patients 1 month after RFA

From: The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma

  NT-RFA (n = 46) C-RFA (n = 84)
Pre-RFA Post-RFA P value Pre-RFA Post-RFA P value
ALT, IU/L 30.4 (21.1–46.3) 34.8 (22.8–69.4) 0.100 31.7 (23.8–46.5) 34.0 (25.0–53.9) 0.941
TBIL, μmol/L 18.8 (14.6–22.7) 18.4 (15.5–25.5) 0.419 17.3 (12.6–21.8) 21.1 (14.1–29.6) 0.233
ALP, IU/L 101.0 (81.8–118.3) 100.0 (86.8–138.8) 0.384 90.0 (77.0–112.0) 110.0 (87.0–145.0) < 0.001
TBA, μmol/L 5.7 (2.5–11.4) 8.1 (2.9–20.0) 0.233 7.6 (2.9–16.2) 5.6 (3.1–13.6) 0.304
AST, IU/L 31.9 (27.0–44.6) 37.9 (30.8–50.7) < 0.001 34.9 (28.4–45.2) 37.7 (31.2–50.0) 0.363
Alb, g/L 44.7 (40.1–46.7) 43.3 (37.9–47.2) 0.149 44.8 (40.1–47.4) 42.5 (30.7–45.8) 0.045
PLT, 10^9/L 122.5 (91.8–163.3) 104.5 (74.0–138.0) < 0.001 118.5 (78.5–147.5) 103.0 (77.0–150.5) 0.112
AFP, ng/mL 22.1 (4.3–224.6) 5.0 (3.0–13.7) < 0.001 13.0 (3.3–105.8) 4.9 (2.8–15.2) < 0.001
  1. RFA radio frequency ablation, ALT alanine aminotransferase, TBIL total bilirubin, ALP alkaline phosphatase, TBA total bile acid, AST aspartate aminotransferase, Alb albumin, PLT platelet count, AFP alpha-fetoprotein